This product is a specific inhibitor of the proton pump in gastric parietal cells. Esomeprazole is the S-isomer of omeprazole. It reduces gastric acid secretion through specific proton pump inhibition, inhibiting both basal gastric acid secretion and stimulated gastric acid secretion. It is concentrated in the high acid environment of the acid secretion microtubules of the parietal cells and converted into an active form, thereby inhibiting the H/K-ATPase (proton pump) in this area.

Esomeprazole is the S-isomer of omeprazole. It reduces gastric acid secretion through a specific targeted mechanism of action and is a specific inhibitor of the proton pump in parietal cells. As a weak base, it is concentrated and converted into an active form in the high acid environment of the acid-secreting microtubules of the parietal cells, thereby inhibiting the H/K-ATPase (proton pump) at this site, inhibiting both basal and stimulated gastric acid secretion. It takes effect within one hour after oral administration, significantly reducing the peak acid secretion caused by pentagastrin stimulation and maintaining an elevated intragastric pH. In addition, the use of antacids may lead to an increase in serum gastrin during treatment, and long-term use may cause an increase in the number of ECL cells and an increased incidence of gastric glandular cysts, but these reactions are benign and reversible.

Based on conventional multiple-dose toxicity, genotoxicity, and reproductive toxicity studies, preclinical studies have not shown that esomeprazole is particularly harmful to humans. Carcinogenicity studies in rats using a racemic mixture have found ECL cell hyperplasia and carcinoid in the stomach. These effects on the stomach in rats are the result of persistent, significant hypergastrinemia. The latter is secondary to a decrease in gastric acid production, which is seen in rats after long-term use of gastric acid secretion inhibitors.

This product can inhibit the synthesis of prostaglandins and has antipyretic and analgesic effects

Antipyretic, analgesic, anti-inflammatory, anti-rheumatic and platelet aggregation inhibitor